These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24865753)

  • 1. Calcium and magnesium for oxaliplatin-induced neuropathy.
    Stansfield L
    Am J Health Syst Pharm; 2014 Jun; 71(12):987-8. PubMed ID: 24865753
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.
    Pachman DR; Ruddy K; Sangaralingham LR; Grothey A; Shah ND; Beutler AS; Hubbard JM; Loprinzi CL
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1097-101. PubMed ID: 26358793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy.
    Atkins CD
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135996
    [No Abstract]   [Full Text] [Related]  

  • 4. New data question treatment for oxaliplatin neurotoxicity.
    Wolf SL
    Clin J Oncol Nurs; 2008 Feb; 12(1):14; author reply 14. PubMed ID: 18323035
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not?
    Avan A; Avan A; Giovannetti E; Peters GJ
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135990
    [No Abstract]   [Full Text] [Related]  

  • 6. Xaliproden lessens oxaliplatin-mediated neuropathy.
    Susman E
    Lancet Oncol; 2006 Apr; 7(4):288. PubMed ID: 16598880
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
    J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
    J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review.
    Jordan B; Jahn F; Beckmann J; Unverzagt S; Müller-Tidow C; Jordan K
    Oncology; 2016; 90(6):299-306. PubMed ID: 27169552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.
    Xu XT; Dai ZH; Xu Q; Qiao YQ; Gu Y; Nie F; Zhu MM; Tong JL; Ran ZH
    J Dig Dis; 2013 Jun; 14(6):288-98. PubMed ID: 23432969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-induced neuropathy: a tale of two electrolytes.
    Babiker HM; Green MR; Nelson MA; Elquza E
    Support Care Cancer; 2015 Jun; 23(6):1483-5. PubMed ID: 25801447
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxaliplatin induced-neuropathy in digestive tumors.
    Sereno M; Gutiérrez-Gutiérrez G; Gómez-Raposo C; López-Gómez M; Merino-Salvador M; Tébar FZ; Rodriguez-Antona C; Casado E
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):166-78. PubMed ID: 24029604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Cavaletti G
    Oncologist; 2011; 16(12):1667-8. PubMed ID: 22128117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to C.d. Atkins and a. Avan et Al.
    Loprinzi CL; Qin R; Grothey A
    J Clin Oncol; 2014 Oct; 32(29):3342-3. PubMed ID: 25135995
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Khattak MA
    Oncologist; 2011; 16(12):1780-3. PubMed ID: 22128115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
    Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
    Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial.
    Afonseca SO; Cruz FM; Cubero Dde I; Lera AT; Schindler F; Okawara M; Souza LF; Rodrigues NP; Giglio Ad
    Sao Paulo Med J; 2013; 131(1):35-8. PubMed ID: 23538593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective.
    Chan A; Chiang J; Lew KY; Chay WY
    J Clin Oncol; 2011 Jun; 29(16):e489; author reply e490-1. PubMed ID: 21482983
    [No Abstract]   [Full Text] [Related]  

  • 20. Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients.
    Wesselink E; Winkels RM; van Baar H; Geijsen AJMR; van Zutphen M; van Halteren HK; Hansson BME; Radema SA; de Wilt JHW; Kampman E; Kok DEG
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29570617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.